0002001011-24-000035.txt : 20240327
0002001011-24-000035.hdr.sgml : 20240327
20240327174759
ACCESSION NUMBER: 0002001011-24-000035
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240325
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Todd C
CENTRAL INDEX KEY: 0001392029
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24792372
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-03-25
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001392029
Davis Todd C
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
1
1
0
0
Chief Executive Officer
0
Common Stock
2024-03-25
4
M
0
7448
46.2
A
111593
D
Common Stock
2024-03-25
4
M
0
2855
67.24
A
114448
D
Common Stock
2024-03-25
4
M
0
2156
68.51
A
116604
D
Common Stock
2024-03-25
4
M
0
3556
66.19
A
120160
D
Non-Qualified Stock Option (right to buy)
46.2
2024-03-25
4
M
0
7448
0.0
D
2032-06-10
Common Stock
7448
0
D
Non-Qualified Stock Option (right to buy)
66.19
2024-03-25
4
M
0
3556
0.0
D
2029-06-06
Common Stock
3556
0
D
Non-Qualified Stock Option (right to buy)
67.24
2024-03-25
4
M
0
2855
0.0
D
2031-06-04
Common Stock
2855
0
D
Non-Qualified Stock Option (right to buy)
68.51
2024-03-25
4
M
0
2156
0.0
D
2030-06-10
Common Stock
2156
0
D
This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023.
This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
2024-03-27